Literature DB >> 3902891

Biochemical and clinical implications of proinsulin conversion intermediates.

B D Given, R M Cohen, S E Shoelson, B H Frank, A H Rubenstein, H S Tager.   

Abstract

Since a complete map of insulin-related peptides in humans requires consideration of proinsulin, Arg32/Glu33-split proinsulin, Arg65/Gly66-split proinsulin, des-Arg31,Arg32-proinsulin, des-Lys64, Arg65-proinsulin, and insulin, we applied high performance liquid chromatography coupled with radioimmunoassay to investigate the formation of proinsulin conversion intermediates in vitro and in vivo. Kinetic analysis of proinsulin processing by a mixture of trypsin and carboxypeptidase B (to stimulate in vivo processes) revealed (a) a rapid decline in proinsulin concommitant with formation of conversion intermediates, (b) formation of des-Arg31, Arg32-proinsulin and des-Lys64,Arg65-proinsulin in the ratio 3.3:1 at steady state, and (c) complete conversion of the precursor to insulin during extended incubation. Studies on normal human pancreas identified a similar ratio of des-Arg31,Arg32-proinsulin to des-Lys64,Arg65-proinsulin (approximately 3:1), whereas two insulinomas contained sizable amounts of des-Arg31,Arg32-proinsulin, but barely detectable amounts of des-Lys64,Arg65-proinsulin. None of the tissues contained measurable quantities of Arg32/Glu33- or Arg65/Gly66-split proinsulin. Analysis of plasma from three diabetic subjects managed by the intravenous infusion of human proinsulin revealed less than 1% processing of the circulating precursor to conversion intermediates and no processing of the precursor to human insulin. Nevertheless, analysis of plasma from the same subjects managed by the subcutaneous infusion of proinsulin revealed 4-11% processing of the precursor to intermediates that had the properties of des-Arg31,Arg32-proinsulin and Arg65/Gly66-split proinsulin. We conclude that (a) processing of proinsulin to insulin in vivo as in vitro likely occurs by preferential cleavage at the Arg32-Glu33 peptide bond in proinsulin, (b) proinsulin is inefficiently processed in the vascular compartment, and (c) subcutaneous administration of the precursor can result in the formation of conversion intermediates with the potential for contributing to biological activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902891      PMCID: PMC424086          DOI: 10.1172/JCI112116

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Binding and degradation of 125I-insulin by rat hepatocytes.

Authors:  S Terris; D F Steiner
Journal:  J Biol Chem       Date:  1975-11-10       Impact factor: 5.157

2.  Plasma proinsulin in patients with functioning pancreatic islet cell tumors.

Authors:  B M Sherman; S Pek; S S Fajans; J C Floyd; J W Conn
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

3.  In vitro studies of the rate of proinsulin and insulin turnover in seven human insulinomas.

Authors:  C Creutzfeldt; N S Track; W Creutzfeldt
Journal:  Eur J Clin Invest       Date:  1973-09       Impact factor: 4.686

4.  Insulin biosynthesis in the rat: demonstration of two proinsulins.

Authors:  J L Clark; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1969-01       Impact factor: 11.205

5.  Biosynthesis of islet cell hormones.

Authors:  H S Tager; C Patzelt; R K Assoian; S J Chan; J R Duguid; D F Steiner
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

6.  Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution.

Authors:  S Shoelson; M Fickova; M Haneda; A Nahum; G Musso; E T Kaiser; A H Rubenstein; H Tager
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

7.  The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes.

Authors:  R M Bergenstal; R M Cohen; E Lever; K Polonsky; J Jaspan; P M Blix; R Revers; J M Olefsky; O Kolterman; K Steiner
Journal:  J Clin Endocrinol Metab       Date:  1984-06       Impact factor: 5.958

8.  Familial hyperproinsulinemia. An autosomal dominant defect.

Authors:  K H Gabbay; K DeLuca; J N Fisher; M E Mako; A H Rubenstein
Journal:  N Engl J Med       Date:  1976-04-22       Impact factor: 91.245

9.  Cocrystallization of proinsulin and insulin.

Authors:  D F Steiner
Journal:  Nature       Date:  1973-06-29       Impact factor: 49.962

Review 10.  Proinsulin and the biosynthesis of insulin.

Authors:  D F Steiner; J L Clark; C Nolan; A H Rubenstein; E Margoliash; B Aten; P E Oyer
Journal:  Recent Prog Horm Res       Date:  1969
View more
  15 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

2.  Kinetic analysis of the type-1 proinsulin endopeptidase by a monoclonal antibody-based immunoadsorbent assay.

Authors:  E M Bailyes; J C Hutton
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

Review 3.  The insulin secretory granule.

Authors:  J C Hutton
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

4.  Proinsulin conversion intermediates: a possible source of confusion.

Authors:  P A Halban
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

5.  Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells.

Authors:  Yan Wang; Yu-Sheng Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  J Control Release       Date:  2011-07-02       Impact factor: 9.776

6.  Proteolytic conversion of proinsulin into insulin. Identification of a Ca2+-dependent acidic endopeptidase in isolated insulin-secretory granules.

Authors:  H W Davidson; M Peshavaria; J C Hutton
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

7.  Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  N Yoshioka; T Kuzuya; A Matsuda; M Taniguchi; Y Iwamoto
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

8.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

9.  High-performance liquid chromatography (HPLC): a rapid, flexible and sensitive method for separating islet proinsulin and insulin.

Authors:  P A Halban; C J Rhodes; S E Shoelson
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

10.  Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats.

Authors:  F Sodoyez-Goffaux; J C Sodoyez; M Koch; C J De Vos; B H Frank
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.